TROVAFLOXACIN

Trovafloxacin is a fluoroquinolone antibacterial agent with a broad sp ectrum of activity. Trovafloxacin has similar or 2-fold lower activity than ciprofloxacin against Enterobacteriaceae and Pseudomonas aerugin osa. Against Haemophilus influenzae and Moraxella catarrhalis, trovafl oxacin has similar activity to ciprofloxacin. Other susceptible Gram-n egative pathogens include Neisseria gonorrhoeae, Chlamydia trachomatis and mycoplasmas. The drug is active against Gram-positive bacteria an d consistently displayed greater activity (2- to 8-fold) than ciproflo xacin against all staphylococci and streptococci tested; activity incl uded methicillin-resistant staphylococci and penicillin-resistant Stre ptococcus pneumoniae. Trovafloxacin has some activity against vancomyc in-resistant enterococci. Anaerobes such as Bacteroides and Clostridiu m spp. are also susceptible to trovafloxacin. Preliminary clinical dat a suggest that trovafloxacin is effective in the treatment of patients with upper and lower respiratory tract and uncomplicated urinary trac t infections and infections caused by C. trachomatis or N. gonorrhoeae . The most frequently noted adverse event with trovafloxacin is dizzin ess which is reported in 11% of patients versus 3% of those receiving comparator agents. Other commonly reported events (>1% of patients) ar e nausea, headache, vomiting, vaginitis and diarrhoea.